Dimension Therapeutics, Inc. (DMTX) [Rocket]

In millions, except per share items	Sep-30-17	Jun-30-17	Mar-31-17	Dec-31-16	Sep-30-16	Jun-30-16	Mar-31-16	Dec-31-15
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Assets
Current assets:
Cash and cash equivalents	14.5	25.1	24.0	30.2	74.9	104.7	117.0	127.0
Marketable securities	19.2	22.4	35.1	47.7	18.8
Accounts receivable	2.8	3.1	2.4	1.9	1.8	1.3	1.3	0.1
Prepaid expenses and other current assets	6.6	6.1	8.6	5.5	2.9	3.7	2.6	2.7
Total current assets	43.1	56.7	70.1	85.3	98.5	109.7	120.9	129.9
Property and equipment, net	6.8	7.3	7.9	8.4	8.7	7.9	6.2	3.3
Deferred offering costs	0.2	0.2	0.2	0.1
Total assets	50.1	64.2	78.2	93.9	107.2	117.6	127.2	133.3

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	1.0	1.3	1.4	2.4	1.4	0.6	2.2	1.6
Accrued expenses and other current liabilities	7.6	3.3	4.3	7.2	7.0	5.5	5.0	3.7
Deferred revenue	10.5	9.9	9.2	8.7	7.8	7.4	7.1	6.8
Notes payable	2.3	2.5	2.5	2.4	2.0	1.4	0.6	0.6
Total current liabilities	21.4	17.0	17.4	20.6	18.1	14.8	15.0	13.2
Deferred revenue, net of current portion	5.1	7.4	9.3	8.7	11.8	13.1	14.5	13.7
Notes payable, net of discount and current portion	2.8	3.3	3.6	4.2	4.8	3.8	0.6	0.8
Other liabilities	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.1
Total liabilities	29.8	28.1	30.7	33.9	35.1	32.3	30.6	27.7

Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; zero shares issued or outstanding at September 30, 2017 and December 31, 2016.
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	163.3	162.1	161.2	160.2	159.2	158.1	157.3	156.8
Accumulated deficit	-142.9	-126.0	-113.7	-100.2	-87.2	-72.8	-60.7	-51.2
Accumulated other comprehensive loss	0.0	-0.1	-0.1	-0.1	0.0
Total stockholders’ equity	20.3	36.1	47.5	59.9	72.0	85.3	96.6	105.6
Total liabilities and stockholders’ equity	50.1	64.2	78.2	93.9	107.2	117.6	127.2	133.3